Back to UBS Group AG UBS Group AG

ACRVACRV
15 quarters

Position history for UBS Group AGUBS Group AG's holdings in ACRIVON THERAPEUTICS INC

UBS Group AG holds 43,850 shares of ACRV (ACRIVON THERAPEUTICS INC), worth $78,053 as of 2026-Q2. The position was increased (+26.6% shares).

Current Value

$78,053

Current Shares

43,850

Total Value Change

+$23,356

Total Shares Change

+39,102

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
43,850
+26.6%
$78,0530.0%$1.78
18
2026-Q1
Decreased
34,634
-90.1%
$48,1410.0%$1.67
0
2025-Q4
Decreased
348,541
-49.0%
$839,9840.0%$2.44
0
2025-Q3
Increased
683,218
+1501x
$1.2M0.0%$1.82
41
2025-Q2
Decreased
455
-96.5%
$5410.0%$1.20
0
2025-Q1
Decreased
12,888
-9.3%
$26,1620.0%$2.24
0
2024-Q4
Increased
14,217
+151.1%
$85,5870.0%$5.41
24
2024-Q3
Decreased
5,662
-49.2%
$39,6340.0%$7.16
0
2024-Q2
Decreased
11,152
-12.5%
$64,6810.0%$5.80
0
2024-Q1
New
12,745
-
$91,1270.0%$7.15
33
2023-Q4
Exited
0
-100.0%
$00.0%$4.92
0
2023-Q3
Decreased
102
-99.0%
$9750.0%$9.56
0
2023-Q2
Increased
9,780
+81.3%
$126,7490.0%$13.32
23
2023-Q1
Increased
5,396
+13.7%
$68,4750.0%$13.79
16
2022-Q4
New
4,748
-
$54,6970.0%$11.52
32

Other major holders of ACRV: RA CAPITAL MANAGEMENT, L.P.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used